The FDA approved Sublocade, Indivior's once-monthly buprenophine injection, to treat opioid use disorder in adults with moderate-to-severe addiction.
Here are four things to know.
1. Buprenophine for opioid use disorder was previously approved to administer in a tablet, dissolving film and implant form. Sublocade provides a new option for patients who may want to reduce the burden of taking a daily tablet.
2. Sublocade is the first monthly injectable buprenophine treatment.
3. The approval comes after an FDA advisory committee voted 18-1 that the injectable drug could benefit addicts.
4. The injection is expected to be available to US patients in the first quarter of 2018.